ControlRad, Inc., an Atlanta, GA-based medical technology company focused on reducing radiation exposure during fluoroscopically guided procedures (FGP), completed $15m in Series B financing.
The round was led by Questa Capital. In addition to the funding, medical device industry veterans Ryan Drant and Tim Patrick have joined its board of directors.
The company intends to use the funds to acceelrate the commercial launch of the ControlRad Trace system.
Led by Guillaume Bailliard, chief executive officer, ControlRad provides FDA-cleared technology that can be integrated into existing mobile C-arms to reduce radiation in any FGP.
With its proprietary semi-transparent filter, tablet and image processing technology, the company’s Trace solution can be retrofitted on existing C-arms. The medical staff draws a region of interest (ROI) on a tablet, which in real-time optimizes image quality in the ROI while reducing unnecessary radiation in the periphery.
The company also has engineering development facilities in Kfar Saba, Israel.